Yu P, Asico L D, Eisner G M, Hopfer U, Felder R A, Jose P A
Department of Pediatrics, Georgetown University School of Medicine, Washington, DC, USA.
Hypertension. 2000 Dec;36(6):1053-8. doi: 10.1161/01.hyp.36.6.1053.
The impaired renal paracrine function of dopamine in spontaneously hypertensive rats (SHR) is caused by hyperphosphorylation and desensitization of the renal D(1) dopamine receptor. Protein phosphatase 2A (PP(2A)) is critical in the regulation of G-protein-coupled receptor function. To determine whether PP(2A) expression and activity in the kidney are differentially regulated in genetic hypertension, we examined the effects of a D(1)-like agonist, fenoldopam, in renal cortical tubules and immortalized renal proximal tubule cells from normotensive Wistar-Kyoto rats (WKY) and SHR. In cortical tubules and immortalized proximal tubule cells, PP(2A) expression and activities were greater in cytosol than in membrane fractions in both WKY and SHR. Although PP(2A) expressions were similar in WKY and SHR, basal PP(2A) activity was greater in immortalized proximal tubule cells of SHR than WKY. In immortalized proximal tubule cells of WKY, fenoldopam increased membrane PP(2A) activity and expression of the regulatory subunit PP(2A)-B56alpha, effects that were blocked by the D(1)-like antagonist SCH23390. Fenoldopam had no effect on cytosolic PP(2A) activity but decreased PP(2A)-B56alpha expression. In contrast, in immortalized proximal tubule cells of SHR, fenoldopam decreased PP(2A) activity in both membranes and cytosol but predominantly in the membrane fraction, without affecting PP(2A)-B56alpha expression; this effect was blocked by the D(1)-like antagonist SCH23390. We conclude that renal PP(2A) activity and expression are differentially regulated in WKY and SHR by D(1)-like receptors. A failure of D(1)-like agonists to increase PP(2A) activity in proximal tubule membranes may be a cause of the increased phosphorylation of the D(1) receptor in the SHR.
自发性高血压大鼠(SHR)中多巴胺的肾旁分泌功能受损是由肾D(1)多巴胺受体的过度磷酸化和脱敏引起的。蛋白磷酸酶2A(PP(2A))在G蛋白偶联受体功能的调节中起关键作用。为了确定在遗传性高血压中肾脏中PP(2A)的表达和活性是否受到不同调节,我们研究了D(1)样激动剂非诺多泮对正常血压的Wistar-Kyoto大鼠(WKY)和SHR的肾皮质小管及永生化肾近端小管细胞的影响。在皮质小管和永生化近端小管细胞中,WKY和SHR的细胞质中PP(2A)的表达和活性均高于膜部分。虽然WKY和SHR中PP(2A)的表达相似,但SHR永生化近端小管细胞中的基础PP(2A)活性高于WKY。在WKY永生化近端小管细胞中,非诺多泮增加了膜PP(2A)活性和调节亚基PP(2A)-B56α的表达,这些作用被D(1)样拮抗剂SCH23390阻断。非诺多泮对细胞质PP(2A)活性无影响,但降低了PP(2A)-B56α的表达。相反,在SHR永生化近端小管细胞中,非诺多泮降低了膜和细胞质中的PP(2A)活性,但主要是在膜部分,且不影响PP(2A)-B56α的表达;这种作用被D(1)样拮抗剂SCH23390阻断。我们得出结论,肾PP(2A)的活性和表达在WKY和SHR中通过D(1)样受体受到不同调节。D(1)样激动剂未能增加近端小管膜中PP(2A)活性可能是SHR中D(1)受体磷酸化增加的一个原因。